ScripCargo Therapeutics’ decision to end all development for its allogeneic cell therapy technology platform and its cancer cell therapy candidates is not the kind of news the biopharmaceutical sector need
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck Obtains Global Rights To Hansoh’
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. In this edition of Deal Watch, we highl
ScripCRISPR Therapeutics AG ’s decision to transition from two earlier gene-edited allogeneic CAR-T cell therapies to next-generation candidates may have come at an opportune time, as concerns have arisen